The Cancer Genome Atlas and the Development of Personalized Therapy

on Friday, October 11, 2013

Clinical trial design for new cancer therapies has historically been focused on a tumor’s tissue of origin, but a Memorial Sloan Kettering paper published on September 26 in Nature Genetics analyzes initial findings from The Cancer Genome Atlas and supports a new approach: one based on the genomic signature of a tumor rather than its tissue of origin.

Memorial Sloan Kettering’s Chair of Computational Biology, Chris Sander, is available to discuss the Nature Genetics study, how the findings may impact current and future treatments, and The Cancer Genome Atlas project.


For more information and to set up an interview, contact the Media Staff.